The Heart of Healthcare | A Digital Health Podcast cover image

🏆 Meet the Shkreli Award "Winners" | Lown Institute President Dr. Vikas Saini

The Heart of Healthcare | A Digital Health Podcast

CHAPTER

Examining Profit Motives in Cancer Drug Dosing Strategies

This chapter examines Amgen's dosing strategy for Lumicross, raising concerns that financial incentives may compromise patient safety. It also critiques the FDA's approval process and the prevalence of maximum tolerated dosage approaches in drug development, suggesting a need for regulatory enhancements.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner